Heron Therapeutics EVP and CFO Ira Duarte received new equity awards. On January 30, 2026, Duarte was granted 216,562 restricted stock units (RSUs) and 216,561 performance stock units (PSUs), each convertible into common stock on a one-for-one basis.
The RSUs vest in 16 equal quarterly installments starting one quarter after the grant date. The PSUs follow the same quarterly schedule but also depend on achieving a net product sales revenue target for fiscal 2026 as reported in the company’s Form 10-K.
Heron Therapeutics director Craig A. Johnson received a grant of 53,960 shares of common stock in the form of restricted stock units. The grant was made on January 30, 2026 at a price of $0 per share, reflecting an equity award rather than an open-market purchase.
The restricted stock units vest in full on January 30, 2027, at which point each unit will convert into one share of common stock. After this grant, Johnson is reported as directly beneficially owning 53,960 shares of Heron Therapeutics common stock.
Heron Therapeutics director Thomas Cusack received an equity award of 53,960 shares of common stock on January 30, 2026. The award was granted as restricted stock units at a price of $0 per share, bringing his directly owned holdings to 53,960 shares.
The restricted stock units vest in full on January 30, 2027, and each unit represents a contingent right to receive one share of Heron Therapeutics common stock once vested. This reflects stock-based director compensation rather than an open‑market purchase.
Heron Therapeutics executive William P. Forbes reported new equity awards. On January 30, 2026, the EVP and Chief Development Officer received 188,315 restricted stock units and 188,314 performance stock units, both at a price of $0 per unit and held directly.
The RSUs convert into common stock on a one-for-one basis and vest in 16 equal quarterly installments starting one quarter after the grant date. The PSUs also vest in 16 equal quarterly installments, but only if a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the company’s Form 10-K, is achieved.
Heron Therapeutics director Sharmila Dissanaike received a grant of 53,960 restricted stock units of common stock. The units were awarded at a price of $0 per share, so she did not pay cash for this equity grant.
The award vests in full on January 30, 2027. Each restricted stock unit represents the right to receive one share of Heron Therapeutics common stock when it vests, giving her 53,960 shares beneficially owned directly after the grant.
Heron Therapeutics (HRTX) granted new equity awards to its Chief Operating Officer, Mark Earl Hensley. On January 30, 2026, he received 188,315 restricted stock units (RSUs) and 188,314 performance stock units (PSUs), each convertible into common stock on a one-for-one basis.
The RSUs vest in 16 equal quarterly installments starting one quarter after the grant date. The PSUs follow the same quarterly schedule but also depend on achieving a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the company’s Form 10-K.
Heron Therapeutics director Adam Morgan reported an equity grant and updated holdings. On January 30, 2026, he acquired 53,960 shares of common stock at a price of $0 through restricted stock units that vest in full on January 30, 2027. After this grant, he directly beneficially owns 123,737 shares of common stock.
An additional 8,753,290 shares of common stock are reported as indirectly owned by Velan Capital Master Fund LP. Mr. Morgan may be deemed to beneficially own these securities through related entities but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.
Heron Therapeutics EVP and CFO Ira Duarte reported an automatic conversion of restricted stock units into common shares. On January 31, 2026, 11,695 restricted stock units were converted into 11,695 shares of common stock at a price of $0 per share under a previously granted equity award.
After this transaction, Duarte directly owned 195,356 shares of common stock and held 140,332 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 16 equal quarterly installments that began on January 31, 2025.
Heron Therapeutics executive William P. Forbes reported the vesting of restricted stock units (RSUs) into common shares. On January 31, 2026, 11,695 RSUs converted into 11,695 shares of common stock at an exercise price of $0.00 per share.
After this transaction, Forbes directly owned 181,773 shares of common stock and 140,332 RSUs. Each RSU represents the right to receive one share of common stock, and the RSUs vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date.
Heron Therapeutics CEO Craig A. Collard, who also serves as a director, reported the vesting and conversion of 34,789 restricted stock units into an equal number of Heron common shares on January 31, 2026 via transaction code M.
Each restricted stock unit represents the right to receive one share of common stock, and these units vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date. Following this transaction, Collard directly holds 571,710 shares of common stock and 417,464 restricted stock units, reflecting his ongoing equity compensation in the company.